期刊文献+

罗格列酮钠治疗2型糖尿病伴代谢综合征患者的临床研究 被引量:5

下载PDF
导出
摘要 目的罗格列酮钠治疗12周后,血糖、糖化血红蛋白、空腹血浆胰岛素、总胆固醇、甘油三酯、舒张压、尿微量血红蛋白及胰岛素抵抗指数较治疗前显著下降,高密度脂蛋白胆固醇、胰岛分泌功能指数增加。方法将136例患者分为罗格列酮钠治疗前及治疗12周后两组,测定其前后血压、心率、体重指数(BMI)肝肾功能、血常规、尿常规、空腹血糖及餐后2h血糖、空腹血浆胰岛素、糖化血红蛋白、血脂及尿微量清蛋白。结果罗格列酮治疗后空腹血糖、餐后2h血糖、糖化血红蛋白、空腹血浆胰岛素、舒张压及尿微量清蛋白均下降(P<0.001)。结论罗格列酮钠与磺脲类和/或双胍类联合用药,能有效地减轻胰岛素抵抗和提高胰岛素分泌功能,降低血糖,调节血脂,同时能控制心血管疾病发生的相关危险因素。
出处 《重庆医学》 CAS CSCD 2006年第10期902-903,共2页 Chongqing medicine
  • 相关文献

参考文献4

  • 1Niemeyer NV,Janney LM.Thiazolidinedione-induced edema[J].Pharmacotherapy,2002,22(7):924
  • 2Komers R,Vrana A.Thiazolidenediones-tools for the research of metabolie syndrome X[J].Physiol Res,1998,4:215
  • 3Wagstaff AJ,Goa KL.Rosiglitazone:a review of its use in the management of type 2 diabetes naellitus[J].Drugs,2002,62(12):1805
  • 4陈家伦.第四讲:噻唑烷二酮类治疗2型糖尿病的疗效及安全性[J].中华内分泌代谢杂志,2000,16(4):268-269. 被引量:48

二级参考文献6

  • 1Porter L E,Freed M I,Jones N P,et al.Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes[].Diabetes.2000
  • 2Rubin C,Egan J,Schneider R.Combination therapy with pioglitazone and insulin in patients with type 2 diabetes[].Diabetes.1999
  • 3Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of Pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus[].Diabetes.2000
  • 4Spiegelman BM.PPARγadipogenic regulator and thiozolidinedione receptor[].Diabetes.1998
  • 5Barman-Balfour JA,Plosker GL.Rosiglitazone[].Drugs.1999
  • 6Lebovitz HE,Salzman A.Rosiglitazone liver safety update[].Diabetes.2000

共引文献47

同被引文献28

  • 1Kawachi H, Koike H, Kurihara H, et al. Cloning of rat nephrin:expression in developing glomeruli and in proteinuric states[J]. Kidney Int, 2000,57 (5) : 1949.
  • 2Topham PS, Kawachi H, Haydar SA, et al. Nephritogenie mAb 5-1-6 is directed at the extracellular domain of rat nephrin[J].J Ciin Invest,1999,104(11) :1559.
  • 3Wickelgren I. First components found for new kidney filter[J]. Science, 1999,286 (5438) : 225.
  • 4Luimula P, Ahola H, Wang SX, et al. Nephrin in experimental glomerular disease[J]. Kid Inter, 2000, 58 (4) : 1461.
  • 5Furness PN, Hall L, Shaw JA, et al. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome[J]. Nephrol Dial Transplant, 1999, 14 ( 5 ) : 1234.
  • 6White KE, Bilous RW. Diabiopsies Study Group. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients [J].Nephrol Dial Transplant, 2004,19:1437.
  • 7Doublier S,Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin Ⅱ[J]. Diabetes, 2003,52 (4):1023.
  • 8Saleem MA, OHare MJ, Reiser J, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression[J]. J Am Soc Nephrol, 2002,13:630.
  • 9Koop K, Eikmans M, Baelde H J, et al. Expression of podocyte associated molecules in acquired human kidney diseases[J]. J Am Soc Neohrol, 2003,14:2063.
  • 10Doublier S,Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin Ⅱ[J]. Diabetes,2003,52 (4):1023.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部